Novel Technologies to assess Gut Health Claims for Carbohydrates

Subthema: 2 - Characterization of biological effects of carbohydrates

Naam trekker: UJF Tietge / HJ VerkadeAffiliatie: UMC Groningen/Dept. of PediatricsContactgegevens: u.j.f.tietge@med.umcg.nl

We are programmmed for disease

General theme: different carbohydrates have differential effects on the balance between health and disease by affecting the intestine at all stages of life

aging

disease

in utero

breast milkvs.

formula feeding

programming

food microbiota

e.g. SCFA

programming

food microbiota

e.g. SCFA

gut health

food microbiota

e.g. SCFA

- direct effects- modulation of programmed risk

Increasing gut health with carbohydrates at all stages of life

(13)CH

conventionalvs.

germ-freevs.

selectivere-constitution/transplantation

Disease models:- atherosclerosis- diabetes (type I and II)- NAFLD/NASH- intest. Inflammation

• in vivo screening platform

• biomarkers (disease-causing signatures of metabolites/ bacterial products)

• novel CHs to test in humans

• leads for health claims

Deliverablesprogramming

Techniques:- atherosclerosis quantitation- GTT/ITT/clamps- Histology- histology/clinical symptoms- stable isotopes to quantitate metabolic fluxes- characterization microbiota- barrier function

Mouse models

Close links to themes 1, 3 and 4

Short-term intervention:- children (lean/obese)- adults (young/elderly/IBD)

• in vivo screening routine for CHs with human relevance

• health claims based on established mechanisms

• novel biomarkers of disease including microbiota

• establish novel CHs as functional food

Deliverables

Human studies

Techniques:- GTT/clamp- biomarkers-stable isotope techniques- SCFA measurements- histology/clinical symptoms- sampling capsule to characterize:

• microbiota• barrier function

ZN Wang et al. Nature 472, 57-63 (2011)

Gut-flora-dependent metabolism of dietary PC and atherosclerosis

(13)CH

conventionalvs.

germ-freevs.

selectivere-constitution/transplantation

Disease models:- atherosclerosis- diabetes (type I and II)- NAFLD/NASH- intest. Inflammation

• in vivo screening platform

• biomarkers (disease-causing signatures of metabolites/ bacterial products)

• novel CHs to test in humans

• leads for health claims

Deliverablesprogramming

Techniques:- atherosclerosis quantitation- GTT/ITT/clamps- Histology- histology/clinical symptoms- stable isotopes to quantitate metabolic fluxes- characterization microbiota- barrier function

Mouse models

Increasing gut health with carbohydrates at all stages of life

ZN Wang et al. Nature 472, 57-63 (2011)

Gut-flora-dependent metabolism of dietary PC and atherosclerosis

Short-term intervention:- children (lean/obese)- adults (young/elderly/IBD)

• in vivo screening routine for CHs with human relevance

• health claims based on established mechanisms

• novel biomarkers of disease including microbiota

• establish novel CHs as functional food

Deliverables

Human studies

Techniques:- GTT/clamp- biomarkers- stable isotope techniques- SCFA measurements- histology/clinical symptoms- sampling capsule to characterize:

• microbiota• barrier function

(13)CH